These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26134364)

  • 1. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia.
    Ong J; Yeung D; Filshie R; Hughes TP; Nandurkar H
    Int J Hematol; 2015 Nov; 102(5):639-42. PubMed ID: 26134364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate.
    Narukawa K; Kakihana K; Fujiwara T; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Intern Med; 2016; 55(1):69-72. PubMed ID: 26726089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib-induced Gastrointestinal Vascular Ectasia in a Patient with Advanced GIST: Case Report and Literature Review.
    Abu-Amna M; Awadie H; Bar-Sela G
    Anticancer Res; 2016 Nov; 36(11):6151-6154. PubMed ID: 27793944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Watermelon stomach: Chronic renal failure and/or imatinib?].
    Montagnac R; Blaison D; Brahimi S; Schendel A; Levasseur T; Takin R
    Nephrol Ther; 2015 Nov; 11(6):496-501. PubMed ID: 26165799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Imatinib-induced gastric antral vascular ectasia" in a reporting system of the Japanese Adverse Drug Event Report database.
    Oshima Y; Yuji K; Tojo A
    Int J Hematol; 2016 May; 103(5):596-8. PubMed ID: 26980219
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
    Saad Aldin E; Mourad F; Tfayli A
    Jpn J Clin Oncol; 2012 May; 42(5):447-50. PubMed ID: 22422898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate induced erythroderma: A rare case series.
    Kumar S; Mahajan BB; Kaur S; Banipal RP; Singh A
    J Cancer Res Ther; 2015; 11(4):993-6. PubMed ID: 26881566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication.
    Moshfeghi K; Nazemizadeh N; Mehrzad V; Hajiannejad A; Esmaeili F; Mohammadbeigi A
    Indian J Cancer; 2015; 52(3):305-7. PubMed ID: 26905120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
    Kaygusuz-Atagunduz I; Toptas T; Yumuk F; Firatli-Tuglular T; Bayik M
    J Cancer Res Ther; 2014; 10(4):1107-8. PubMed ID: 25579564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
    Singh S; Sharma PK
    Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
    Sun X; Cai X; Yang J; Chen J; Guo C; Cao P
    Mol Cells; 2016 Dec; 39(12):869-876. PubMed ID: 27989101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
    Li Y; Wang CL; Din B; Yu L; Zhu J
    Acta Haematol; 2017; 137(3):158-162. PubMed ID: 28399540
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia.
    Alshehry NF; Kortan P; Lipton JH
    Clin Case Rep; 2014 Jun; 2(3):77-8. PubMed ID: 25356253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia.
    Eliacik E; Isik A; Aydin C; Uner A; Aksu S; Sayinalp N; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Haznedaroglu IC
    Hematology; 2015 Aug; 20(7):392-6. PubMed ID: 25517484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia.
    Jeyaraman P; Naithani R
    J Pediatr Hematol Oncol; 2020 Jan; 42(1):e64-e65. PubMed ID: 31688623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
    Carulli G; Baratè C; Marini A; Ottaviano V; Cervetti G; Fontanelli G; Guerrini F; Arici R; Guerri V; Di Paolo A; Polillo M; Ferreri MI; Galimberti S; Petrini M
    Hematol Oncol; 2015 Dec; 33(4):250-2. PubMed ID: 25256816
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.
    Shepherd P; Dhanapala C; Maguire C; White J; Drummond M; Holyoake T; Johnson PR
    Scott Med J; 2008 Aug; 53(3):8-12. PubMed ID: 18780518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.